STORY: :: Bristol Myers Squibb :: FileDrugmakers plan to raise U.S. prices for at least 350 brand-name drugs in 2026, including vaccines and the blockbuster cancer treatment Ibrance.::CVSThat’s according to data provided exclusively to Reuters by health research firm 3 Axis Advisors.The raises come as the Trump administration pressures drugmakers for cuts.::CVSWhile the number of price increases has increased compared to the same point last year, the average price increase of 4 percent is in line with 2025.The increases do not reflect any rebates given to pharmacy benefit managers and other reductions.:: Boehringer IngelheimDrugmakers also plan to cut list prices for about nine drugs, including the diabetes treatment Jardiance, which will drop by 40%.It’s among 10 drugs the U.S. government is negotiating a lower price for in 2026 for the Medicare program for people ages 65 and older.:: PfizerA health policy researcher told Reuters that these deals were touted as transformative, but actually eroded margins in terms of what is causing the high prices of prescription drugs in the United States.::CVSU.S. patients currently pay by far the most for prescription drugs; This is generally almost three times higher than in other developed countries.Pfizer announced that the list prices of approximately 80 different drugs, including the cancer drug Ibrance, and the COVID vaccine, which increased by 15%, had the highest increase in list prices.:: Pfizer:: FilePfizer said in a statement that it has set the 2026 average list price of its innovative drugs and vaccines below the general inflation rate.::CVSMore price increases and cuts can be expected in early January, which has historically been the month when drug manufacturers increase prices the most.